trial

Effects of Cariprazine on Cardiac Repolarization in Patients With Schizophrenia

NCTId NCT01376076
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 129 (actual)
Sponsored by Forest Laboratories
Primary completion 2012-02
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
129 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2011-06
Primary completion
2012-02
Eligibility
ALL · 18 Years · 50 Years

Interventions & indications

Drugs
Cariprazine (Vraylar)Risperidone

Sponsors

Forest LaboratoriesLead Sponsor

Investigators

1
Suneeta Ahuja, PhDStudy Director

Sites

4 total
Glendale, United StatesLong Beach, United StatesWillingboro, United StatesHouston, United States

Facts & assertions

4 sourced
Enrollment
129
Phase
PHASE1
Primary Completion Date
2012-02
Status
COMPLETED
relationships
The graph out of here
drug
Cariprazine (Vraylar)
drug
Risperidone
drug
lead_sponsor
Forest Laboratories
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Suneeta Ahuja, PhD
person